Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation : Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation
The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
ClinicalTrials.gov - (2020) vom: 29. Mai Zur Gesamtaufnahme - year:2020 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: May 19, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 |
---|
Study ID: |
NCT04393233 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003395537 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003395537 | ||
003 | DE-627 | ||
005 | 20230425230935.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2020 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003395537 | ||
035 | |a (UBBS_Klinische_Studien)NCT04393233 | ||
035 | |a (UBBS_Klinische_Studien)RHUMACOVID ( 29BRC20.0110) | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation |b Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: May 19, 2020, Last downloaded: ClinicalTrials.gov processed this data on June 14, 2021, Last updated: June 15, 2021 | ||
520 | |a The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis. | ||
650 | 2 | |a Arthritis | |
650 | 2 | |a Arthritis, Rheumatoid | |
650 | 4 | |a Medical Condition: Rheumatoid Arthritis, COVID | |
650 | 4 | |a Study Type: Observational | |
650 | 4 | |a Recruitment Status: Recruiting | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2020) vom: 29. Mai |
773 | 1 | 8 | |g year:2020 |g day:29 |g month:05 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04393233 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2020 |b 29 |c 05 |